By educating elected officials and other government decision-makers on the needs of the cystic fibrosis community, the Cystic Fibrosis Foundation works to shape public policy to help our efforts to cure CF and provide all people with CF the opportunity to live full, healthy lives. Below find a listing of our state and federal statements, letters, and regulatory comments.
Statements, letters, and regulatory comments issued before July 2023 can be found in our archive.
In a letter to California's Assembly Committee on Health, the Cystic Fibrosis Foundation expressed its support for AB 2180, which, if passed, would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements, as well as require covered benefits to be considered essential health benefits.
In response to a request for information from the U.S.
In a letter to the Tennessee Senate Committee on Commerce and Labor, the Cystic Fibrosis Foundation expressed support for SB 2008 which would require covered benefits to be considered essential health benefits and limit alternative funding programs in state-regulated plans.
In a letter to the Tennessee House Insurance Subcommittee, the Cystic Fibrosis Foundation expressed support for two bills: HB 2557, which would direct the state to apply for a waiver for continuous coverage for children under age 6, and HB 2170, which would require covered benefits to be considered essential health benefits.
In a letter to the Illinois House Health Care Availability & Accessibility Committee and the Illinois House Insurance Committee, the Cystic Fibrosis Foundation expressed support for two bills — HB 4504, which would limit copays for prescription inhalers, and HB 5051, which would prohibit prior authorization on long-term prescriptions.
In a letter to Missouri's House Committee on Health and Mental Health Policy, the Cystic Fibrosis Foundation expressed its support for HB 1628, which would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements.
In a letter to Oregon's Senate Committee on Health Care, and later to the full Senate, the Cystic Fibrosis Foundation expressed its support for HB 4113, which would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements.
In a letter to Maryland's Senate Finance Committee and House Health and Government Operations Committee, the Cystic Fibrosis Foundation expressed its support for HB 879/SB 595, which would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements as well as ban alternative funding prog
In a letter to Connecticut's House Committee on Insurance and Real Estate, the Cystic Fibrosis Foundation provided feedback on HB 5054 which would establish an affordability board with the goal to improve access to and affordability of care for Connecticuters.
In a letter to Nebraska's Banking, Commerce and Insurance Committee, the Cystic Fibrosis Foundation provided feedback on LB 833 which would establish an affordability board with the goal to improve access to and affordability of care for Nebraskans.
In a letter to the Virginia Senate Committee on Commerce and Labor, the Virginia House Committee on Labor and Commerce, and all members of the House of Delegates, the Cystic Fibrosis Foundation provided feedback on SB 274/HB 570 which would establish an affordability board with the goal to improve access to and affordability of care for Virginia
In a letter to select Florida legislators, the Cystic Fibrosis Foundation expressed its support of SB 228/HB 363, which would ban co-pay accumulator programs in the state.
In a letter to Wisconsin’s Assembly Committee on Health, Aging, and Long-Term Care, the Cystic Fibrosis Foundation expressed their support of AB 773 which would ban co-pay accumulators in the state and require covered benefits to be considered essential health benefits.
In a letter to the Insurance Subcommittee of South Carolina's House Labor, Commerce, and Industry Committee, the Foundation expressed its support for H.3618 which would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements, as well as ban maximizer programs and alternative programs
In a letter to all Utah legislators, the Cystic Fibrosis Foundation expressed its support for SB 152, which would require insurers to apply third-party assistance to out-of-pocket maximums and other patient cost-sharing requirements.
In a letter to Vermont's Senate Committee on Health and Welfare, the Cystic Fibrosis Foundation provided feedback on S 98 which would give the Green Mountain Care Board the ability to cap the purchase price of certain drugs with the goal to improve access to and affordability of care for Vermonters.